



Glycometabolic Control in Older Patients with Type 2 Diabetes

Guest Editor:

Dr. Valeria Calsolaro

Geriatrics Unit, Department of
Clinical and Experimental
Medicine, University of Pisa, Pisa,
Italy

Deadline for manuscript
submissions:

closed (15 March 2023)

Message from the Guest Editor

Dear Colleagues,

Type 2 diabetes mellitus (T2DM) is a chronic condition with an increasing prevalence worldwide, especially in the older population. T2DM leads to micro- and microvascular complications, cognitive impairment, and risk of falls, fractures, and frailty. The ideal management of T2DM therapy in such a peculiar population could not disregard a broad evaluation of frailty, in order to set a glycemic target appropriate for the life expectancy and the reserve which the older patients present, as also underlined in the most recent guidelines. Incredibly interesting would then be a detailed discussion about what the new therapeutic targets should be, especially in view of the new therapeutic strategies brought forth by new available drugs with a wide spectrum of action. Interest should particularly be addressed to older patients, both in the acute care setting and in the chronic one, considering the interplay with frailty, chronic diseases such as cardiovascular and renal impairment, and polytherapy.

Dr. Valeria Calsolaro
Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Dr. Amedeo Lonardo

1. Formerly Director of the Simple Operating Unit "Metabolic Syndrome", Azienda Ospedaliero-Universitaria, 41126 Modena, Italy
2. Formerly Professor of Internal Medicine, School of Specialization of Allergology and Clinical Immunology, University of Modena and Reggio Emilia, 41121 Modena, Italy

Message from the Editor-in-Chief

The metabolome is the result of the combined effects of genetic and environmental influences on metabolic processes. Metabolomic studies can provide a global view of metabolism and thereby improve our understanding of the underlying biology. Advances in metabolomic technologies have shown utility for elucidating mechanisms which underlie fundamental biological processes including disease pathology. *Metabolites* is proud to be part of the development of metabolomics and we look forward to working with many of you to publish high quality metabolomic studies.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (*Biochemistry and Molecular Biology*) / CiteScore - Q2 (*Endocrinology, Diabetes and Metabolism*)

Contact Us

Metabolites Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/metabolites
metabolites@mdpi.com
[X@MetabolitesMDPI](https://twitter.com/MetabolitesMDPI)